NCT00839111Unknown2 期
A Phase Ⅱ Open Label, Non Randomized Study, in Which Sorafenib is Used in Combination With Irinotecan, Leucovorin and Fluorouracil in Patients With Advanced Colorectal Cancer After Failure of Oxaliplatin Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Progression-Free Survival (PFS) ,defined as the time from treatment to disease progression or death due to any cause
研究概览
简要总结
The purpose of this study is to evaluate the Progression-Free Survival (PFS) time of Sorafenib in combination with FOLFIRI regimen used as in the second front treatment in patients with advanced CRC after failure of oxaliplatin treatment.
详细描述
This is a phase Ⅱ open label, non randomized study, in which sorafenib is used in combination with irinotecan, leucovorin and fluorouracil in patients with advanced colorectal cancer after failure of oxaliplatin treatment.The aim of this study is to determine the Progression-Free Survival (PFS) of Sorafenib used in combination with FOLFIRI regimen as a second front treatment in patients with advanced CRC after failure of oxaliplatin treatment, defined as the time from treatment to disease progression or death due to any cause. The other secondary endpoints are disease control rate, defined as complete response, partial response, and stable disease.Response rate,overall survival, and safety are also evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of written informed consent
- •Histological or cytological confirmed adenocarcinoma of the colon or rectum
- •Age between 18 and 75 years.
- •Patient with metastatic disease failed after at least 2 cycles of oxaliplatin-based systemic chemotherapy, excluding adjuvant chemotherapy. Disease progression should be proven by radiological evidence. A duration of 28 days after oxaliplatin therapy is also required.
- •ECOG Performance Status of 0 or1
- •Life expectancy of at least 12 weeks
- •The required evidence of measurable lesions should be at least 10 mm in the longest diameter by spiral computed tomography scan or 20 mm with conventional techniques (RECIST criteria)
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •Hemoglobin > 9.0 g/dl
- •Absolute neutrophil count (ANC) >1,500/mm3
- •Platelet count 100,000/μl
- •Total bilirubin < 1.5 times the upper limit of normal ALT and AST < 2.5 x ULN(< 5 x ULN for patients with liver involvement of their cancer)
- •ALP< 4 x ULN
- •PT-INR/PTT < 1.5 x upper limit of normal
- •Serum creatinine < 1.5 x ULN
排除标准
- •Patients unable to swallow oral medications
- •History of cardiac disease:
- •congestive heart failure >NYHA class 2
- •active CAD (MI more than 6 mo prior to study entry is allowed)
- •cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension
- •History of HIV infection or chronic hepatitis B or C (high copy number of HBV).
- •Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry)
- •Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •History of organ allograft ,The organ allograft may be allowed as protocol specific.
- •Patients undergoing renal dialysis
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma within 5 years.
- •Patients with evidence or history of bleeding diathesis.Significant haemorrhage (>30 ml/bleeding episode in previous 3 months),haemoptysis (>5 ml fresh blood in previous 4 weeks) or thrombotic event (including transient ischaemic attack) in the previous 12 months.
- •chronic inflammatory bowel disease; ileus; genetic fructose intolerance
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- •Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial (and men for at least 3 months after last administration of study medication).
- •Prior exposure to the study drug.
研究组 & 干预措施
A
Experimental
Sorafenib plus FOLFIRI regimen
干预措施: sorafenib (Drug)
A
Experimental
Sorafenib plus FOLFIRI regimen
干预措施: FOLFIRI (Drug)
结局指标
主要结局
Progression-Free Survival (PFS) ,defined as the time from treatment to disease progression or death due to any cause
时间窗: every 8 weeks
次要结局
- Secondary endpoints are disease control rate, defined as a complete response, partial response, and stable disease; Response rate and overall survival; and safety are also evaluated.(every 8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) TherapyBreast CancerNCT00493636Accelerated Community Oncology Research Network160
已完成
2 期
BATTLE Program: Sorafenib in Patients With NSCLCLung CancerNCT00411671M.D. Anderson Cancer Center105
已完成
2 期
Sorafenib in Relapsed High Grade OsteosarcomaOsteosarcomaNCT00889057Italian Sarcoma Group35
终止
2 期
Sorafenib in Resected Non-small Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungNCT00532025Johannes Gutenberg University Mainz134
进行中（未招募）
1 期
A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159